查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1983915

生物製造关键蛋白市场：按产品类型、原料、应用、最终用途和分销管道分類的全球市场预测－2026-2030年

Vital Proteins for Biomanufacturing Market by Product Type, Source, Application, End-Use, Distribution Channel - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年生物製造关键蛋白质市场价值为 565.2 亿美元，预计到 2025 年将成长至 614.7 亿美元，年复合成长率为 9.00%，到 2030 年将达到 948.1 亿美元。

主要市场统计数据
基准年 2024 565.2亿美元
预计年份：2025年 614.7亿美元
预测年份 2030 948.1亿美元
复合年增长率 (%) 9.00%

权威概述了胶原蛋白、明胶和水解物如何帮助现代生物製造工作流程并推动跨学科创新。

关键蛋白质是生物製造的基础材料，为生命科学和商业领域的广泛应用提供必要的结构、功能和生物活性。在生物製造中，胶原蛋白、明胶和胶原蛋白水解物具有至关重要的性能特征。胶原蛋白支持组织支架的建构和机械完整性，明胶可用于成型、包覆和控释，而水解物则提供适用于製剂和细胞讯号传导的水溶性生物活性胜肽。这三类材料构成了一个材料复杂性的连续光谱，为组织工程、药物递送、再生医学和功能性营养等领域的创新提供了支持。

生物技术原料采购、永续性措施和先进加工技术如何融合，从而改变关键蛋白质应用中的供应链和材料性能？

在生物製造的关键蛋白质领域，正在发生多项变革性变化，这些变化正在重新定义上游采购和下游应用。首先，生物技术主导的采购正在加速重组蛋白和工程化表现平台的应用。这些技术减少了对传统动物性原料的依赖，提高了批次间的一致性，并实现了对功能域的序列级控制。这种转变支持了医疗和製药领域的应用，这些领域对可追溯性和降低免疫抗原性风险的要求很高。其次，出于对永续性的关注，製造商正在寻求低碳且符合伦理的替代方案，尤其重视海洋资源和产品特定的价值提升策略。这些趋势与供应链多元化和新型认证系统的建立密切相关。

评估近期针对蛋白质原料的关税措施如何影响供应链，并改变筹资策略、库存管理和创新重点。

近期影响蛋白质原料和中间投入品的贸易政策措施对采购、生产和购买决策产生了连锁反应。对某些动物性和加工蛋白进口产品的关税调整增加了依赖跨境原料流动的製造商的接收成本，促使他们迅速审查供应商组合和合约条款。因此，一些公司优先考虑近岸外包、长期固定价格合约或投资国内加工能力，以降低价格波动并维持受监管终端用途的生产连续性。

全面的細項分析表明，产品类型、原材料变化、应用需求、最终用途要求和分销模式如何共同影响策略和规格决策。

一套精细的细分框架揭示了每种产品类型、原材料、应用、最终用途和分销管道的不同需求、风险特征和商业策略。胶原蛋白、明胶和水解物等产品类型的差异，对应不同的技术规格和加工需求。在胶原蛋白中，I型、II型和III型的功能作用分别需要不同的分析控制和针对特定应用的关注点；而A型和B型明胶则影响凝胶特性和配方行为。水解物根据其高低分子量分布进行区分，在生物活性和溶解度方面表现出不同的性能特征，这些特征直接指南医疗和营养应用领域的配方决策。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和需求模式决定了采购、监管和商业化的优先事项。

区域趋势持续影响关键蛋白质全球价值链的策略重点和竞争定位。在美洲，成熟的畜牧业和发达的水产养殖业为牛和猪源性原料的稳定供应提供了保障，而不断增长的营养保健品和机能性食品市场则推动了对高纯度水解物和胶原蛋白衍生物的需求，尤其是在消费者配方方面。该地区的监管执法和自愿性可追溯性计划提高了人们对产品品质的期望，许多製造商正在投资建立透明的供应链和认证体系，以促进跨境贸易和临床应用。

深入了解老牌製造商、特殊​​原料製造商和新兴生物技术参与企业如何透过合併、差异化和策略联盟来竞争。

关键蛋白质领域的竞争格局呈现出复杂多样的态势，既有老牌生产商，也有特种原料供应商，还有利用生技的新兴参与企业。老牌供应商持续投资于製程管制、认证和规模化生产，以满足动物营养和大众市场个人照护等大量生产需求。同时，特种原料供应商则透过高纯度医用级产品、先进的分馏技术以及针对特定营养补充剂和药品应用的客製化胜肽开发来脱颖而出。生技领域的新兴参与企业则透过引入重组表达平台和精准设计的序列，重塑了竞争格局，挑战了传统的采购模式。

为领导企业提供切实可行的策略行动，以降低供应风险、提高材料性能，并透过伙伴关係和有针对性的研发抓住高附加价值机会。

产业领导企业应优先采取一系列切实可行的措施，以应对供应波动、日益复杂的监管环境以及对先进蛋白质材料不断变化的需求。首先，投资于多元化的筹资策略，将传统来源与海洋来源、重组来源和产品特定来源结合，以降低单一来源供应中断的风险，并回应不断变化的客户偏好。其次，加快製程改善和分析能力的提升，从而严格控制分子量分布、交联度和纯度，提供满足医疗保健和製药客户严苛要求的材料。第三，透过第三方认证、生产历史（监管链）文件和生命週期评估，永续性市场。

实证调查方法：结合专家访谈、技术文献分析、供应链映射和情境评估，得出可操作的见解。

本分析的调查方法整合了多种证据来源，旨在为关键蛋白质领域提供严谨且切实可行的观点。主要定性资料透过与製造商、材料科学家、配方专家、法规顾问和通路合作伙伴进行结构化访谈所获得，以了解实际营运、技术限制和商业策略。次要研究涵盖同行评审的科学文献、专利申请、标准文件和法规指南，以检验技术声明并阐明医疗保健、製药和消费品应用领域的监管环境。

一项权威的综合分析突显了策略重点，将供应链韧性、材料工程和监管合规性转化为竞争优势。

总之，生物技术的发展、对永续性的需求以及市场的成熟，共同提升了胶原蛋白、明胶和水解物在生物製造领域的战略重要性。这些材料不再只是普通的原料，而是经过工程改造的组分，其在医疗、製药和先进营养等领域的高价值应用适用性取决于其分子特性、来源和监管状态。随着价值链适应不断变化的贸易政策，以及新的生产方法日益普及，那些兼具卓越技术、多元化采购管道和清晰品质保证体系的企业将获得显着优势。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生物製造的关键蛋白质市场：依产品类型划分

  • 亲和性和配体和结合蛋白质
    • 蛋白质A
    • 蛋白质G
    • 蛋白质L
    • 链霉亲和素/亲和素
  • 载体蛋白
    • 白蛋白
    • 铁蛋白和其他
    • 转铁蛋白
  • Chaperone和摺迭辅助因子
    • 分子伴侣
    • 蛋白质二硫键异构酶
  • 酵素
    • 糖苷酶
    • 激酶
    • 纱布
    • 核酸酶
    • 聚合酵素
    • 蛋白酶
  • 细胞外基质和包被
    • 胶原蛋白
    • 纤连蛋白
    • 层黏连蛋白
    • 玻璃粘连蛋白
  • 生长因子和细胞激素
    • EGF家族
    • FGF家族
    • IGF/胰岛素家族
    • 白细胞介素和趋化素
    • TGF-β/BMP家族
    • VEGF/PDGF家族
  • 血清替代
    • 预先定义的蛋白质混合物
    • 重组白蛋白混合物

第九章 生物製造的关键蛋白质市场：依来源划分

  • 动物源性
  • 无细胞系统
  • 哺乳动物细胞系统
  • 微生物表现系统
  • 植物来源
  • 重组

第十章：生物製造的关键蛋白质市场：按应用领域划分

  • 动物饲料
    • 水产饲料
    • 牲畜饲料
    • 宠物食品
  • 化妆品
    • 护髮
    • 口腔护理
    • 护肤
  • 医疗设备
    • 鹰架材料
    • 外科植入
    • 伤口敷料
  • 营养保健品
    • 骨骼健康
    • 关节健康
    • 皮肤健康
    • 运动营养
  • 製药
    • 药物输送
    • 组织工程
    • 创伤治疗

第十一章 生物製造的关键蛋白质市场：依最终用途划分

  • 学术和研究机构
  • 合约研究组织（CRO）
  • 製药和生物技术公司

第十二章：生物製造的关键蛋白质市场：依分销管道划分

  • 直销
  • 销售代理

第十三章：生物製造的关键蛋白质市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 生物製造的关键蛋白质市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 生物製造的关键蛋白质市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国生物製造关键蛋白质市场

第十七章：中国生物製造关键蛋白市场

第十八章 竞争格局

  • 2024年市场集中度分析
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2024 年
  • 2024年产品系列分析
  • 基准分析，2024 年
  • Danaher Corporation
  • Darling Ingredients Inc.
  • Gelita AG
  • Humabiologics, Inc
  • Lonza Group AG
  • Merck KGaA
  • Nitta Gelatin, Inc.
  • Thermo Fisher Scientific Inc.
  • Weishardt International
Product Code: MRR-D47730F51F28

The Vital Proteins for Biomanufacturing Market was valued at USD 56.52 billion in 2024 and is projected to grow to USD 61.47 billion in 2025, with a CAGR of 9.00%, reaching USD 94.81 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 56.52 billion
Estimated Year [2025] USD 61.47 billion
Forecast Year [2030] USD 94.81 billion
CAGR (%) 9.00%

An authoritative overview of how collagen, gelatin, and hydrolysates enable modern biomanufacturing workflows and drive crossdisciplinary innovation

Vital proteins function as foundational materials in biomanufacturing, supplying structural, functional, and bioactive properties essential to a broad array of life science and commercial applications. Within biomanufacturing, collagen, gelatin, and collagen-derived hydrolysates provide key performance attributes: collagen supports tissue scaffolding and mechanical integrity; gelatin enables molding, encapsulation, and controlled release; and hydrolysates offer soluble bioactive peptides suited to formulation and cellular signaling. Together, these classes form a continuum of material complexity that underpins innovations in tissue engineering, drug delivery, regenerative medicine, and functional nutrition.

As industry actors increasingly integrate biotechnology and materials science, the role of these proteins has expanded from commodity ingredients to engineered biomaterials. This transition has been driven by advances in recombinant expression systems, process-scale purification, and tailored molecular modification. Consequently, researchers and manufacturers now demand consistent molecular profiles, traceable raw materials, and regulatory-compliant production pathways. The introduction of recombinant and nontraditional sources is reshaping supply strategies, while downstream processing improvements are enabling higher-purity grades and performance-tuned variants that meet the rigorous needs of clinical and high-value commercial uses.

Given these dynamics, stakeholders must reconcile material performance with sourcing risk, regulatory trajectory, and commercialization timelines. Effective decision-making requires integrated visibility into product differentiation across collagen types and gelatin classes, the implications of molecular weight distributions in hydrolysates, and the alignment of material specifications with application-level requirements in medical devices, pharmaceuticals, and advanced nutrition.

How biotechnology sourcing, sustainability commitments, and advanced processing are converging to transform supply chains and material performance in vital protein applications

The landscape for vital proteins in biomanufacturing is undergoing several transformative shifts that are redefining both upstream sourcing and downstream application. First, biotechnology-driven sourcing is accelerating adoption of recombinant proteins and engineered expression platforms that reduce reliance on traditional animal sources while improving batch-to-batch consistency and enabling sequence-level control of functional domains. This shift, in turn, supports medical and pharmaceutical use-cases that demand traceability and reduced immunogenic risk. Second, sustainability considerations are elevating marine and byproduct valorization strategies as manufacturers seek lower-carbon, ethically aligned alternatives; these trends interact with supply chain diversification initiatives and new certification schemes.

Concurrently, advances in material science and processing are expanding the functional envelope of these proteins. Precision hydrolysis and fractionation techniques allow producers to tailor molecular weight distributions and peptide profiles to optimize bioactivity, solubility, and rheology for specific applications. In parallel, integrated manufacturing models are bringing bioprocessing, formulation, and device assembly closer together, facilitating co-development of materials and products and shortening innovation cycles. Regulatory evolution also plays a formative role: clearer pathways for medical-grade materials and harmonized quality standards are enabling faster adoption in implantable devices and tissue-engineering constructs. Altogether, these shifts are fostering an ecosystem where material innovation, ethical sourcing, and regulatory clarity converge to unlock new commercial opportunities.

Assessment of how recent tariff measures on protein inputs have propagated through supply chains to alter sourcing strategies, inventory management, and innovation priorities

Recent trade policy measures affecting proteinaceous raw materials and intermediate inputs have produced cascading operational and strategic effects across sourcing, manufacturing, and procurement decisions. Tariff adjustments imposed on certain animal-derived and processed protein imports have elevated landed costs for manufacturers that rely on cross-border raw material flows, prompting rapid reassessment of supplier portfolios and contract terms. As a result, some firms prioritized nearshoring, long-term fixed-priced contracts, or investment in domestic processing capabilities to mitigate volatility and maintain production continuity for regulated end uses.

Beyond direct cost effects, tariff-driven shifts have impacted supplier behavior and inventory management practices. Manufacturers have responded by increasing safety stocks for critical inputs and accelerating qualification of alternative sources, including marine and recombinant supply streams, to preserve product timelines and regulatory traceability. In addition, the policy environment has intensified focus on tariff classification and valuation strategies, as well as on optimizing inbound logistics to minimize duty exposure through strategic routing and free trade agreement utilization.

Importantly, tariffs also influenced innovation choices. Facing elevated input expense, some developers reallocated R&D budgets toward process intensification, yield improvements, and higher-value product formulations that reduce raw material intensity per unit of value. Consequently, the cumulative impact of trade measures extended beyond short-term cost inflation to encourage structural changes in sourcing strategies, manufacturing investments, and product design decisions that enhance resilience and long-term competitiveness.

Comprehensive segmentation analysis showing how product types, source variants, application demands, end-use requirements, and distribution models jointly shape strategy and specification decisions

A nuanced segmentation framework reveals differentiated requirements, risk profiles, and commercial strategies across product types, sources, applications, end uses, and distribution channels. Product type distinctions among collagen, gelatin, and hydrolysates correspond to divergent technical specifications and processing needs; within collagen, the functional roles of Type I, Type II, and Type III demand separate analytical controls and application focus, while gelatin classes Type A and Type B influence gelation properties and formulation behavior. Hydrolysates differentiated by high and low molecular weight profiles command distinct performance characteristics in bioactivity and solubility, which directly inform formulation decisions for medical versus nutritional applications.

Source-based segmentation highlights tradeoffs between traditional and emerging supply streams. Bovine, marine, and porcine origins each carry unique regulatory, cultural, and safety considerations, while recombinant production offers sequence-defined materials with enhanced traceability and reduced zoonotic risk. Application segmentation ties material selection tightly to end-function: animal nutrition formulations require tailored peptide profiles for digestibility and palatability; cosmetics prioritize sensory and skin interaction properties across hair care, oral care, and skin care; medical device developers focus on scaffold mechanics, implant compatibility, and wound dressing performance; nutraceuticals and pharmaceutical developers demand rigorous bioactivity, stability, and delivery characteristics for bone, joint, skin, sports nutrition, drug delivery, and tissue-engineering uses.

End-use segmentation further refines commercial pathways, as product specifications for animal nutrition, dietary supplements, functional foods, medical applications, and personal care diverge in regulatory regimes, quality expectations, and channel economics. Distribution channel segmentation underscores how institutional sales, offline retail, and online retail impose different packaging, labeling, and supply cadence requirements, with institutional buyers such as food service and healthcare institutions seeking bulk supply agreements and stringent certification, while brand websites and e-commerce platforms emphasize direct-to-consumer traceability and shelf-ready presentation. Together, these segmentation dimensions create a matrix of technical and commercial considerations that companies must navigate to align product development, manufacturing, and go-to-market strategies.

Regional dynamics and demand patterns across the Americas, Europe Middle East Africa, and Asia Pacific that determine sourcing, regulation, and commercialization priorities

Regional dynamics continue to shape strategic priorities and competitive positioning across the global value chain for vital proteins. In the Americas, established livestock industries and developed aquaculture sectors support a steady supply of bovine and porcine raw materials, while a growing nutraceutical and functional food market drives demand for high-purity hydrolysates and collagen derivatives tailored for consumer-facing formulations. Regulatory enforcement and voluntary traceability programs in this region reinforce quality expectations, prompting many manufacturers to invest in transparent supply chains and certification schemas that facilitate cross-border trade and clinical translation.

In Europe, Middle East, and Africa, a complex mix of regulatory jurisdictions, sustainability priorities, and rising medical device activity is accelerating demand for ethically sourced and marine-derived proteins. The region's emphasis on environmental compliance and circularity fosters innovation in byproduct valorization and alternative sourcing, while harmonization efforts across regulatory authorities create clearer pathways for medical-grade materials. Meanwhile, the Asia-Pacific region remains a major production and consumption hub, underpinned by large-scale aquaculture, expanding consumer markets for beauty and health products, and rapid adoption of recombinant and marine technologies. This region's cost-efficient manufacturing base, combined with rising domestic R&D capacity, positions it as both an exporter of raw materials and an increasingly sophisticated developer of finished formulations and devices.

Taken together, these regional insights emphasize the need for diversified sourcing strategies, regulatory agility, and market-specific product positioning. Companies that align production footprints, quality systems, and commercial channels with regional demand characteristics will be better equipped to capture cross-border opportunities and respond to localized regulatory and consumer trends.

Insights into how legacy producers, specialty ingredient firms, and biotech entrants are competing through integration, differentiation, and strategic collaboration

Competitive dynamics among companies in the vital proteins space reflect a blend of legacy producers, specialty ingredient firms, and new entrants leveraging biotechnology. Established suppliers continue to invest in process control, certification, and scale to serve high-volume applications such as animal nutrition and mass-market personal care, while specialty firms differentiate through high-purity medical-grade offerings, advanced fractionation capabilities, and custom peptide development for targeted nutraceutical and pharmaceutical uses. New biotechnology entrants are reshaping the competitive set by introducing recombinant expression platforms and precision-engineered sequences that challenge conventional sourcing assumptions.

Strategic approaches vary: some companies pursue integrated value chains that combine raw material sourcing, downstream purification, and formulation services to capture margin and accelerate time to market; others adopt asset-light models, focusing on proprietary formulations, branding, and channel partnerships to scale presence in direct-to-consumer and institutional channels. Mergers, strategic partnerships, and contract manufacturing collaborations have become common mechanisms to acquire technical capabilities or expand geographic reach without committing to greenfield capacity. Across the competitive landscape, one recurring theme is the premium placed on traceability, quality systems, and regulatory alignment, especially for suppliers targeting medical devices and pharmaceutical applications. Companies that invest in robust quality management systems, transparent provenance, and technical support services position themselves as preferred partners for high-value, regulated customers, while those prioritizing cost leadership maintain competitiveness in large-volume consumer segments.

Practical strategic actions for leaders to reduce supply risk, enhance material performance, and capture highvalue opportunities through partnerships and targeted R and D

Industry leaders should prioritize a set of pragmatic actions to navigate supply volatility, regulatory complexity, and shifting demand for advanced protein materials. First, invest in diversified sourcing strategies that combine traditional sources with marine, recombinant, and byproduct-derived streams to reduce exposure to single-source disruptions and to meet evolving customer preferences. Second, accelerate adoption of process improvements and analytical capabilities that enable tight control over molecular weight distribution, crosslinking, and purity, thereby delivering materials that meet the stringent requirements of medical and pharmaceutical customers. Third, strengthen quality, traceability, and sustainability credentials through third-party certification, chain-of-custody documentation, and lifecycle assessments to differentiate offerings and facilitate market access across jurisdictions.

Additionally, prioritize strategic partnerships and flexible manufacturing agreements to scale rapidly without incurring disproportionate capital risk. Invest selectively in R&D that targets high-margin applications where materials science and bioactivity confer defensible product advantages, such as tissue-engineered scaffolds, drug-delivery matrices, and clinically validated nutraceuticals. Finally, align commercial models with channel-specific needs by offering formulation support, tailored packaging, and technical training for institutional buyers, while developing direct-to-consumer narratives that emphasize provenance, efficacy, and sustainability. Implementing these actions in a coordinated manner will enhance resilience, accelerate innovation, and maximize commercial returns across a range of end markets.

An evidence driven methodology combining expert interviews, technical literature analysis, supply chain mapping, and scenario evaluation to support actionable insights

The research methodology underpinning this analysis integrates multiple evidence streams to produce a rigorous, actionable perspective on the vital proteins landscape. Primary qualitative inputs include structured interviews with manufacturers, material scientists, formulation experts, regulatory advisers, and channel partners to capture operational realities, technical constraints, and commercial strategies. Secondary review encompassed peer-reviewed scientific literature, patent filings, standards documentation, and regulatory guidance to validate technical assertions and to map the regulatory context for medical, pharmaceutical, and consumer applications.

Analytical processes involved crosswalks between product specifications and application requirements to identify performance gaps and opportunities, coupled with supply chain mapping to reveal sourcing dependencies and logistic vulnerabilities. Scenario analysis explored plausible policy and trade developments, manufacturing scale pathways, and technology adoption curves to assess strategic implications. Throughout the methodology, emphasis was placed on triangulation of findings and on documenting source provenance to ensure confidence in conclusions. Where heterogeneity existed in respondent perspectives, the analysis highlighted areas of consensus and divergence to support informed decision-making rather than singular predictive claims.

A decisive synthesis highlighting the strategic priorities that convert supply chain resilience, material engineering, and regulatory alignment into competitive advantage

In conclusion, the confluence of biotechnology, sustainability imperatives, and market sophistication is elevating the strategic importance of collagen, gelatin, and hydrolysates within biomanufacturing. These materials are no longer solely commodity inputs; they are engineered components whose molecular characteristics, provenance, and regulatory posture determine suitability for high-value applications in medicine, pharmaceuticals, and advanced nutrition. As supply chains adjust to trade policy shifts and as new production modalities gain traction, companies that marry technical excellence with diversified sourcing and clear quality documentation will capture disproportionate value.

Moving forward, the path to competitive advantage rests on three interconnected priorities: secure and verifiable supply chains, invest in process and analytical capabilities that deliver application-specific performance, and pursue market strategies that align product attributes with regional regulatory expectations and channel requirements. By focusing resources where material differentiation creates defensible commercial advantage, organizations can turn current disruptions into catalysts for innovation and sustainable growth in next-generation biomanufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vital Proteins for Biomanufacturing Market, by Product Type

  • 8.1. Affinity Ligands & Binding Proteins
    • 8.1.1. Protein A
    • 8.1.2. Protein G
    • 8.1.3. Protein L
    • 8.1.4. Streptavidin/Avidin
  • 8.2. Carrier Proteins
    • 8.2.1. Albumins
    • 8.2.2. Ferritin & Others
    • 8.2.3. Transferrins
  • 8.3. Chaperones & Folding Aids
    • 8.3.1. Chaperonins
    • 8.3.2. Protein Disulfide Isomerase
  • 8.4. Enzymes
    • 8.4.1. Glycosidases
    • 8.4.2. Kinases
    • 8.4.3. Ligases
    • 8.4.4. Nucleases
    • 8.4.5. Polymerases
    • 8.4.6. Proteases
  • 8.5. Extracellular Matrix & Coatings
    • 8.5.1. Collagens
    • 8.5.2. Fibronectins
    • 8.5.3. Laminins
    • 8.5.4. Vitronectin
  • 8.6. Growth Factors & Cytokines
    • 8.6.1. EGF Family
    • 8.6.2. FGF Family
    • 8.6.3. IGF/Insulin Family
    • 8.6.4. Interleukins & Chemokines
    • 8.6.5. TGF-Beta/BMP Family
    • 8.6.6. VEGF/PDGF Family
  • 8.7. Serum Replacements
    • 8.7.1. Defined Protein Mixes
    • 8.7.2. Recombinant Albumin Blends

9. Vital Proteins for Biomanufacturing Market, by Source

  • 9.1. Animal-Derived
  • 9.2. Cell-Free Systems
  • 9.3. Mammalian Cell Systems
  • 9.4. Microbial Expression Systems
  • 9.5. Plant-Based
  • 9.6. Recombinant

10. Vital Proteins for Biomanufacturing Market, by Application

  • 10.1. Animal Nutrition
    • 10.1.1. Aquaculture Feed
    • 10.1.2. Livestock Feed
    • 10.1.3. Pet Food
  • 10.2. Cosmetics
    • 10.2.1. Hair Care
    • 10.2.2. Oral Care
    • 10.2.3. Skin Care
  • 10.3. Medical Devices
    • 10.3.1. Scaffold Materials
    • 10.3.2. Surgical Implants
    • 10.3.3. Wound Dressings
  • 10.4. Nutraceuticals
    • 10.4.1. Bone Health
    • 10.4.2. Joint Health
    • 10.4.3. Skin Health
    • 10.4.4. Sports Nutrition
  • 10.5. Pharmaceuticals
    • 10.5.1. Drug Delivery
    • 10.5.2. Tissue Engineering
    • 10.5.3. Wound Healing

11. Vital Proteins for Biomanufacturing Market, by End-Use

  • 11.1. Academic & Research Institutions
  • 11.2. Contract Research Organizations (CROs)
  • 11.3. Pharmaceutical & Biotechnology Companies

12. Vital Proteins for Biomanufacturing Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributors

13. Vital Proteins for Biomanufacturing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Vital Proteins for Biomanufacturing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vital Proteins for Biomanufacturing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Vital Proteins for Biomanufacturing Market

17. China Vital Proteins for Biomanufacturing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2024
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2024
  • 18.3. Product Portfolio Analysis, 2024
  • 18.4. Benchmarking Analysis, 2024
  • 18.5. Danaher Corporation
  • 18.6. Darling Ingredients Inc.
  • 18.7. Gelita AG
  • 18.8. Humabiologics, Inc
  • 18.9. Lonza Group AG
  • 18.10. Merck KGaA
  • 18.11. Nitta Gelatin, Inc.
  • 18.12. Thermo Fisher Scientific Inc.
  • 18.13. Weishardt International

LIST OF FIGURES

  • FIGURE 1. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY END-USE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 13. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN A, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN A, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN G, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN G, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN G, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN L, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN L, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN L, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STREPTAVIDIN/AVIDIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STREPTAVIDIN/AVIDIN, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STREPTAVIDIN/AVIDIN, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ALBUMINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ALBUMINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ALBUMINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FERRITIN & OTHERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FERRITIN & OTHERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FERRITIN & OTHERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSFERRINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSFERRINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSFERRINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN DISULFIDE ISOMERASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN DISULFIDE ISOMERASE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN DISULFIDE ISOMERASE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GLYCOSIDASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GLYCOSIDASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GLYCOSIDASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY KINASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY KINASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY KINASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIGASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIGASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIGASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUCLEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUCLEASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUCLEASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY POLYMERASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY POLYMERASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY POLYMERASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COLLAGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COLLAGENS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COLLAGENS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FIBRONECTINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FIBRONECTINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FIBRONECTINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LAMININS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LAMININS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LAMININS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VITRONECTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VITRONECTIN, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VITRONECTIN, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 84. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EGF FAMILY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 85. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EGF FAMILY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 86. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EGF FAMILY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FGF FAMILY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 88. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FGF FAMILY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FGF FAMILY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 90. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY IGF/INSULIN FAMILY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 91. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY IGF/INSULIN FAMILY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY IGF/INSULIN FAMILY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 93. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERLEUKINS & CHEMOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 94. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERLEUKINS & CHEMOKINES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERLEUKINS & CHEMOKINES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 96. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TGF-BETA/BMP FAMILY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 97. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TGF-BETA/BMP FAMILY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 98. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TGF-BETA/BMP FAMILY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VEGF/PDGF FAMILY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 100. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VEGF/PDGF FAMILY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VEGF/PDGF FAMILY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 102. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 103. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, 2018-2030 (USD MILLION)
  • TABLE 106. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DEFINED PROTEIN MIXES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 107. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DEFINED PROTEIN MIXES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DEFINED PROTEIN MIXES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT ALBUMIN BLENDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 110. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT ALBUMIN BLENDS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT ALBUMIN BLENDS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL-DERIVED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 114. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL-DERIVED, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL-DERIVED, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 116. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 117. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 118. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 119. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MAMMALIAN CELL SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 120. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MAMMALIAN CELL SYSTEMS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 121. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MAMMALIAN CELL SYSTEMS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 122. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 123. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PLANT-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 126. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PLANT-BASED, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 127. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PLANT-BASED, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 129. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 130. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 133. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, 2018-2030 (USD MILLION)
  • TABLE 136. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AQUACULTURE FEED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 137. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AQUACULTURE FEED, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AQUACULTURE FEED, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 139. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIVESTOCK FEED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 140. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIVESTOCK FEED, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIVESTOCK FEED, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 142. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PET FOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 143. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PET FOOD, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PET FOOD, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 145. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COSMETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 146. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COSMETICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 147. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COSMETICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 148. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COSMETICS, 2018-2030 (USD MILLION)
  • TABLE 149. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY HAIR CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 150. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY HAIR CARE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 151. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY HAIR CARE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 152. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ORAL CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 153. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ORAL CARE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 154. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ORAL CARE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 155. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SKIN CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 156. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SKIN CARE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 157. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SKIN CARE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 159. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDICAL DEVICES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 160. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDICAL DEVICES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 161. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 162. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SCAFFOLD MATERIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 163. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SCAFFOLD MATERIALS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 164. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SCAFFOLD MATERIALS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 165. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SURGICAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 166. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SURGICAL IMPLANTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 167. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SURGICAL IMPLANTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 168. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY WOUND DRESSINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 169. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY WOUND DRESSINGS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY WOUND DRESSINGS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 171. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 172. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 173. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 174. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 175. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY BONE HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 176. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY BONE HEALTH, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 177. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY BONE HEALTH, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 178. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY JOINT HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 179. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY JOINT HEALTH, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY JOINT HEALTH, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SKIN HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 182. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SKIN HEALTH, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 183. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SKIN HEALTH, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 184. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SPORTS NUTRITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 185. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SPORTS NUTRITION, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SPORTS NUTRITION, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 187. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 188. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 189. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 190. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 191. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 192. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 193. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 194. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 195. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 196. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 197. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 198. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY WOUND HEALING, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 199. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 200. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 201. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 202. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 203. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 205. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 206. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 207. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 208. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 209. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 210. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 212. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 214. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 215. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 216. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 217. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 218. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 219. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 221. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 222. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, 2018-2030 (USD MILLION)
  • TABLE 223. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
  • TABLE 224. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, 2018-2030 (USD MILLION)
  • TABLE 225. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 226. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, 2018-2030 (USD MILLION)
  • TABLE 227. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 228. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, 2018-2030 (USD MILLION)
  • TABLE 230. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COSMETICS, 2018-2030 (USD MILLION)
  • TABLE 231. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 232. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 233. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 234. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 235. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 237. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 239. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 240. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, 2018-2030 (USD MILLION)
  • TABLE 241. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
  • TABLE 242. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, 2018-2030 (USD MILLION)
  • TABLE 243. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 244. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, 2018-2030 (USD MILLION)
  • TABLE 245. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 246. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, 2018-2030 (USD MILLION)
  • TABLE 248. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COSMETICS, 2018-2030 (USD MILLION)
  • TABLE 249. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 250. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 251. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 252. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 253. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 255. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 257. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 258. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, 2018-2030 (USD MILLION)
  • TABLE 259. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
  • TABLE 260. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, 2018-2030 (USD MILLION)
  • TABLE 261. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 262. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, 2018-2030 (USD MILLION)
  • TABLE 263. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 264. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, 2018-2030 (USD MILLION)
  • TABLE 266. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COSMETICS, 2018-2030 (USD MILLION)
  • TABLE 267. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 268. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 269. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 270. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 271. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)

TABLE